--Medical aesthetics manufacturer also reintroduces TempSure™ Vitalia
hand piece and continues to market MonaLisa Touch® laser--
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Hologic, Inc.’s (Nasdaq: HOLX)
Cynosure division announced today the North American launch of the
FDA-cleared TempSure™
Surgical RF technology, a new offering of the TempSure™
radiofrequency (RF) platform that provides clinicians the ability to
perform both surgical and non-surgical aesthetic procedures across a
variety of specialties, on a single device.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181213005589/en/
TempSure Surgical RF technology (Photo: Business Wire)
Cynosure also has returned TempSure™
Vitalia hand pieces and probes to the market and will continue
to market its MonaLisa
Touch® CO2 laser following the U.S. Food and Drug
Administration (FDA) inquiry on products used in energy-based women’s
health procedures. Over the past several months, Cynosure worked closely
with the FDA and reviewed and updated all its marketing and promotional
materials to ensure they are consistent with the FDA’s labeling
expectations.
TempSure Surgical RF technology harnesses a 300-watt and 4-MHz
radiofrequency platform that enables precise incisions with minimal
lateral thermal damage to surrounding tissues. The resulting
high-quality coagulation lessens sparking and charring during
procedures, which promotes quicker recovery and better healing for
patients1. The device is designed to improve patient
satisfaction and aesthetic outcomes, and can be used by clinicians
across a variety of specialties including plastic surgery, dermatology,
gynecology and ophthalmology.
“We’re continually innovating to ensure our customers set themselves
apart with effective and diverse treatment offerings, and this enhanced
platform is a gamechanger across specialties,” said Kevin Thornal,
Hologic's Division President, Cynosure. “The cutting-edge technology of
the TempSure platform will now allow doctors to transition seamlessly
from invasive to non-invasive treatments on one device.”
Thornal added, “We’re pleased to reintroduce TempSure Vitalia and to
continue offering MonaLisa Touch to provide clinically strong products
for women’s wellness. Cynosure is the only medical aesthetic
manufacturer to offer two different energy-based modalities for women’s
wellness — radiofrequency and CO2 — and we remain committed
to advancing women’s pelvic health around the globe.”
TempSure Surgical RF technology is designed to enhance the
existing TempSure radiofrequency platform, and includes a variety of
electrodes that integrate seamlessly with the main TempSure unit.
In January 2018, Cynosure launched the TempSure radiofrequency
platform with TempSure™
Envi, a device for treating facial fine lines and wrinkles,
tightening the skin through soft tissue coagulation, and temporarily
reducing the appearance of cellulite. New and existing customers now
have the opportunity to customize their TempSure Envi system to
include TempSure Surgical RF technology, TempSure Vitalia hand pieces,
or a combination of all three to help meet different clinical needs at
their practice.
“TempSure Surgical is truly a breakthrough technology that has improved
my surgical procedures and delivered fantastic results,” said Dr. Barry
DiBernardo of New Jersey Plastic Surgery. “I immediately noticed cleaner
cuts and optimum coagulation during surgery, which gives me the
confidence to tell my patients they will experience less bruising and
better wound healing. With the addition of TempSure Surgical, I am now
able to perform improved surgical incisions and also offer noninvasive
wrinkle reduction with TempSure Envi. This technology has revolutionized
my practice — and it will revolutionize your practice.”
To learn more about the TempSure radiofrequency platform, please visit www.cynosure.com/tempsure-platform.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily
focused on improving women’s health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic and The Science of Sure, and associated logos are registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United States
and/or other countries. Cynosure is a registered trademark of Cynosure,
Inc. and TempSure is a trademark of Cynosure, Inc. MonaLisa Touch is
a registered trademark owned by DEKA.
Forward-Looking Statements
This news release may contain forward-looking information that involves
risks and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated in
any particular manner with respect to an individual patient, as the
actual effect of the use of the products can only be determined on a
case-by-case basis. In addition, there can be no assurance that these
products will be commercially successful or achieve any expected level
of sales. Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or statements
are based.
1 With less tissue destruction, healing is accelerated and
patients can recover quickly. Bridenstine, J.B., Derm Surgery (1998);
vol 24, p397-400.
SOURCE: Hologic, Inc.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181213005589/en/
Media Contact:
Jane Mazur
+1
508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael Watts
+1
858.410.8588
michael.watts@hologic.com
Source: Hologic, Inc.